Peter N. Morcos

Medicine · Health Sciences

22h-index4.9kcitations73works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(52), Cancer Genomics and Diagnostics(22), Lung Cancer Research Studies(18), Hepatitis C virus research(14), Multiple and Secondary Primary Cancers(12)

Publications73 total

Abstract 4348: A translational pharmacokinetic-pharmacodynamic (PKPD) modeling framework of novel, highly selective, next-generation allosteric cyclin-dependent kinase 2 (CDK2) inhibitors
Cancer Research·2025· 1 cited
Abstract C126: Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling of novel covalent Kelch-like ECH-associated protein 1 (KEAP1) activators
Molecular Cancer Therapeutics·2023
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Data from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Data from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Data from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Data from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i>+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
2023Open Access
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase<i>–</i>positive non‐small cell lung cancer
CPT Pharmacometrics & Systems Pharmacology·2021· 14 citedOpen Access
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
Lung Cancer·2019· 30 cited
page 1 of 4Next →

Frequent Co-authors

Bogdana Balas(17), Ali Zeaiter(16), Walter Bordogna(13), Barbara J. Brennan(12), Elena Guerini(11), Alice T. Shaw(10), Sai‐Hong Ignatius Ou(10), Patrick F. Smith(10), Sophie Golding(9), Luigi De Petris(9), Shirish M. Gadgeel(8), Jin Seok Ahn(7), Tony Mok(7), Ramaswamy Govindan(7), James Chih‐Hsin Yang(7), Dong‐Wan Kim(6), Li Yu(6), Fabrice Barlési(6), Anne‐Marie C. Dingemans(6), Neil Parrott(6)